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AbstrACt
Objectives Isoniazid preventive therapy (IPT), for people living 
with HIV (PLHIV) is the proven and recommended intervention to 
avert tuberculosis (TB). In 2015, Nepal implemented 6 months 
of IPT for all PLHIV registered for HIV care in antiretroviral 
therapy (ART) centres. After programmatic implementation, 
there has been no systematic assessment of IPT initiation 
and completion rates among PLHIV. We aimed to assess IPT 
initiation and completion rates in the Far-Western Region (FWR) 
of Nepal.
Design We conducted a retrospective cohort study using 
secondary data extracted from registers maintained at ART 
centres.
setting All 11 ART centres in the FWR of Nepal.
Participants All PLHIV registered for care between January 
2016 and December 2017 in 11 ART centres.
Primary outcome measures IPT initiation and completion 
rates were summarised as percentages with 95% CI. 
Independent association between patient characteristics and 
non-initiation of IPT was assessed using cluster-adjusted 
generalised linear model (log binomial regression) and adjusted 
relative risk (RR) with 95% CI was calculated.
result Of the 492 PLHIV included, 477 (97.0%) did not have 
active TB at registration. Among 477 without active TB, 141 
(29.8%, 95% CI 25.7% to 34.1%) had been initiated on IPT and 
85 (17.8%) were initiated within 3 months of registration. Of 
141 initiated on IPT, 133 (94.3%, 95% CI 89.1% to 97.5%) had 
completed 6 months of IPT. Being more than 60 years of age 
(RR-1.3, 95% CI 1.1 to 1.7), migrant worker (RR-1.3, 95% CI 
1.1 to 1.4) and not being initiated on ART (RR-1.4, 95% CI 1.1 to 
1.8) were significantly associated with IPT initiation.
Conclusions In FWR of Nepal, three out of 10 eligible PLHIV 
had received IPT. Among those who have received IPT, the 
completion rate was good. The HIV care programme needs to 
explore the potential reasons for this low coverage and take 
context specific corrective action to fix this gap.
IntrODuCtIOn
Tuberculosis (TB) is the leading cause of 
mortality among people living with HIV 
(PLHIV).1 Globally, around 400 000 TB 
related deaths occurred among PLHIV in 
2017, accounting for about one-third of 
all-cause mortality.1 2 Prevention, early diag-
nosis and treatment of TB can therefore help 
avert significant number of deaths among 
PLHIV.
In 2008, to decrease the TB burden among 
PLHIV, the WHO recommended ‘Three I’s 
strategy’ consisting of three interventions: 
(i) intensified TB case finding and linkage 
to high-quality anti-TB treatment (ii) TB 
prevention using isoniazid preventive therapy 
(IPT) and early antiretroviral therapy (ART), 
irrespective of CD4 count and clinical staging 
and (iii) infection control in HIV care facili-
ties and other congregate settings.3–5
Early initiation of ART is a standalone 
intervention to reduce TB incidence among 
PLHIV and TB burden in countries with 
high prevalence of HIV.6–11 Since most coun-
tries have adopted ‘test and treat’ strategy 
for PLHIV, ART coverage has improved with 
around 21.7 million PLHIV on ART in 2017.2 
strengths and limitations of this study
 ► First study from resource limited Far-Western 
Region of Nepal on isoniazid preventive therapy (IPT) 
implementation.
 ► Minimal scope for selection bias as all the people 
living with HIV (PLHIV) registered for care in the 11 
antiretroviral therapy centres in the region were 
included.
 ► Study was conducted in programmatic setting and 
10% of data extraction forms were validated by 
principal investigator.
 ► Use of secondary data with potential documentation 
errors and incompleteness.
 ► Possibility of overestimation of the proportion eligi-
ble for IPT, as all PLHIV without active tuberculosis 
were considered as eligible for IPT.
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Though ART reduces the risk of TB among PLHIV, ART 
alone may not be enough to bring down the risk of 
developing TB among PLHIV to that of HIV negative 
individuals.12 13 Hence, there is a evidence based need 
for interventions like IPT to complement the effect of 
ART.
IPT for 6 or 36 months has proven to be beneficial in 
reducing the risk of TB in both adults and children.14–16 
Studies have reported that IPT and ART have a syner-
gistic effect in reducing the burden of TB and mortality 
among PLHIV.17–21 Although the WHO recommended 
IPT for PLHIV in 2004, majority of the countries did 
not implement IPT in their HIV care programme.22 
Globally, only about 42% of all the newly diagnosed 
PLHIV were started on IPT in 2016.1 Also, studies have 
reported varied IPT completion rates ranging from 64% 
to 96%.23–28
Nepal, a landlocked country in South Asia, is experi-
encing a concentrated HIV epidemic with an overall 
estimated prevalence of 0.3%. Nepal has substantial TB 
burden with estimated 45 000 new TB patients (incidence 
rate of 152 per 100 000 population) and 6900 deaths due 
to TB in 2017.1 In Nepal, TB is ranked as the sixth leading 
cause of death and is thus considered as a major public 
health problem.29
In 2012, sentinel surveillance estimated high preva-
lence (11%) of TB among PLHIV.30 In the wake of this, 
the National Centre for AIDS and Sexually Transmitted 
Disease Control (NCASC) and National TB Centre 
(NTC) jointly implemented IPT as a pilot programme 
in five ART centres located in tertiary care hospitals in 
December 2012. Operational research conducted during 
this pilot phase reported low IPT initiation rate (32%) 
but high completion rate (87%).27 In December 2015, 
IPT for PLHIV was scaled up to all ART centres in the 
country. However, there has been no evaluation of IPT 
coverage and completion rates after programmatic imple-
mentation of IPT in Nepal.
Far-Western Region (FWR, also known as Province 
seven) of Nepal is an under developed region with 
highest prevalence of job-related outward migration.31 
The region has low literacy and high poverty levels.31 
There is anecdotal evidence that TB/HIV care provision 
is complicated in the region due to poor healthcare facili-
ties and outward migration leading to attrition from care.
Though IPT has been implemented in the ART centres 
of the FWR of Nepal since January 2016, no concurrent 
evaluations have been conducted to assess the coverage 
and completion rates of IPT. There is an anecdotal 
evidence of poor IPT coverage in the region. Systematic 
assessment of IPT coverage and completion rates will 
help the programme managers to revisit the strategies 
adopted and take corrective actions. Therefore, this study 
was planned to assess the IPT coverage and completion 
rate, and to identify key sociodemographic and baseline 
clinical characteristics associated with non-initiation of 
IPT.
MethODOlOgy
study design
A cohort study was conducted using secondary data 
collected routinely by the National HIV programme.
study setting
General setting
This study was carried out in the ART centres of FWR of 
Nepal. The FWR is one of the five developmental regions 
of the Nepal; Eastern, Central, Western, Mid-Western and 
Far-Western Region. The region has nine districts and a 
population of around 2.5 million.32 The region has poor 
health indicators, high prevalence of poverty (40%) and 
low literacy rate (30%).33 Due to lack of job opportunities 
and poverty in the region, there is job-related migration 
to cities of Nepal and India. With concentrated epidemic 
among the outward migrants, the region has relatively 
higher estimated HIV prevalence (0.4%) compared with 
the national estimate (0.3%).34
specific setting
There are 11 ART centres in the FWR Region which are 
colocated with district hospital or tertiary care centres. 
At least one ART centre is present in each of the nine 
districts of the region. The NCASC under Ministry of 
Health and Population provides HIV treatment and care 
services through these ART centres. All services in these 
ART centres are provided free of cost.
HIV testing and linking to HIV care in the region
HIV testing services are provided through ‘Voluntary 
Counselling and Testing centres’ (VCTC) located in the 
secondary level public health facilities. All ART centres 
also have VCTC facilities. In VCTC, those individuals 
detected to be seropositive for HIV are counselled and 
referred to the nearby ART centres for care and treat-
ment. All the laboratory and clinical examination details 
during registration and follow-up are documented in the 
ART register maintained at ART centres.
Patients successfully referred to ART centre are regis-
tered in the ‘ART register’ of ART centre with a unique 
‘ART ID number’. As per ‘test and treat’ policy, all regis-
tered PLHIV are initiated on appropriate ART by the ART 
medical officer after clinical and laboratory evaluation.35 
After providing adherence counselling, once-daily fixed-
dose combination (FDC) drugs are dispensed for 15 days. 
If the individual is found to be adherent, the drugs are 
dispensed for a period 1 month.
Isoniazid preventive therapy for PLHIV
Since 2016, HIV/TB comprehensive package was imple-
mented in the ART centres of the region. All newly regis-
tered PLHIV are screened for active TB using the WHO 
symptom screen and national TB guidelines (cough, 
excessive night sweat, fever for >2 weeks and weight loss 
of >3 kg with in 4 weeks) during their first visit. Individuals 
with any of the four symptoms are evaluated for TB using 
sputum smear microscopy and chest radiography. After 
evaluation, those PLHIV without TB and without known 
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liver disease, active alcohol use, prior isoniazid resis-
tance, peripheral neuropathy and unexplained illness 
are considered eligible to receive IPT and IPT should be 
dispensed to them by the ART medical officer.
PLHIV who are eligible for IPT receive isoniazid 
(300 mg for adults and 200 mg for children) and pyri-
doxine (25 mg) for 6 months. The IPT drugs are dispensed 
along with ART drugs during monthly visit to ART centre. 
IPT is stopped in case PLHIV develops active TB or severe 
adverse drug events. The details of the drugs dispensed, 
adverse drug reaction and completion of the IPT are 
recorded in ‘IPT register’ maintained at ART centres.
study population
PLHIV registered in ART centres of FWR, Nepal during 
January 2016 to December 2017 were eligible for the 
study. The minimum sample size was calculated to be 204, 
assuming percentage of IPT initiation to be 32%,27 rela-
tive precision of 20% and 95% CI. However, we included 
all PLHIV registered during the reference period.
Data variables, sources of data and data collection
Data variables like ART ID number, age, gender, marital 
status, education, occupation, mode of HIV transmis-
sion, tobacco use, alcohol use, date of registration at ART 
centre, date of HIV testing, WHO clinical staging at base-
line, CD4 count, ART start date, ART regimen, TB disease 
during registration, liver disease at registration, neurop-
athy at registration, severe illness at registration and date 
of IPT initiation were extracted from the ‘ART register’. 
The outcome variables like IPT status, IPT completion, 
date of IPT completion and reasons for non-completion 
were extracted from the ‘IPT register’. Self-designed data 
collection proforma was used to extract details from the 
registers.
Six trained ‘data collectors’ extracted data during June–
August 2018. The principal investigator visited each ART 
centre at least once during the data collection period and 
verified at least 10% of the proformas filled by each ‘data 
collector’ for quality and completeness.
Operational definition
IPT eligible: PLHIV without active TB or not diagnosed 
with TB within 3 months of ART registration in whom 
there is no documented evidence of liver disease, active 
alcohol use, jaundice, prior isoniazid resistance, periph-
eral neuropathy and unexplained illness in the ‘ART 
register’ during initial assessment.
IPT initiation: IPT is said to be initiated when the eligible 
PLHIV receives IPT after eligibility assessment.
IPT completion: The IPT is said to be completed if the 
individual started on IPT receives it during six consecutive 
visits to ART centre and is indicated as ‘IPT completed’ 
in ‘IPT register’.
Data entry and analysis
Data were double entered and validated using EpiData 
V.3.1 entry software. Data were analysed using Stata V.12.0 
software. Categorical variables like IPT eligibility, IPT 
initiation, IPT initiation within 3 months and IPT comple-
tion were summarised as percentages with 95% CI.
The association between sociodemographic and base-
line clinical characteristics with not initiating of IPT was 
assessed using bivariate log binomial regression. Unad-
justed relative risk (RR) with 95% CI was calculated as 
measure of association. To assess the independent associ-
ation, a cluster (ART centre) adjusted generalised linear 
model (Poisson regression) with variables having p value 
<0.25 in the univariate log binomial regression was devel-
oped. Adjusted RR with 95% CI was calculated. Quantita-
tive variables like age and CD4 level were classified into 
appropriate class intervals prior to calculating adjusted 
RR with 95% CI.
sensitivity analysis
In the current study, except for details of TB symptom 
screening and diagnosis of TB, none of the other details 
on IPT eligibility criteria (liver disease, active alcohol use, 
jaundice, prior isoniazid resistance, peripheral neurop-
athy and unexplained illness) were documented in the 
‘ART registers’. Hence, only those with active TB could 
be considered as not eligible for IPT. Sensitivity analysis 
was conducted to accommodate for potential deficiency 
in documentation of IPT eligibility examination results.
Patient and public involvement
Principal investigator and the data collectors did not 
interact directly with the PLHIV registered for care in the 
ART centres during this retrospective record review. The 
investigators interacted with the ART centre in-charge, 
counsellors and peer educators of all the ART centres 
included in the study. Findings from this study will help 
the national TB programme and NCASC programme of 
Nepal to identify the gaps in IPT implementation and 
eventually improve the care and treatment of PLHIV.
results
Between January 2016 and December 2017, a total of 
492 PLHIV had been registered at ART centres of FWR, 
Nepal. Of 492 PLHIV, 267 (54%) were male and the mean 
(SD) age was 3614 years. Sociodemographic and clinical 
characteristics are described in table 1. Of total, 8% were 
children (0–14 years) and 3% were elderly (≥60 years). 
At the time of registration, 44% were in WHO clinical 
staging III or IV. Of total, 98% were initiated on ART and 
majority of them (86%) were on tenofovir, lamivudine, 
efavirenz regimen in FDC. The details on education and 
occupation status were missing for more than 50% of the 
study participants.
Of the total 492 PLHIV, 15 (3.0%) had been diagnosed 
with active TB; 11 had TB at the time of registration 
and four were diagnosed within 3 months. In total, 477 
(97.0%, 95% CI 95.0% to 98.3%) PLHIV were eligible for 
IPT. Of 477 PLHIV, 85 (17.8%, 95% CI 14.5% to 21.6%) 
were initiated on IPT within 3 months of registration and 
56 (11.7%) were initiated later. Median (IQR) duration 
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between registration and initiation of IPT was 41 (0–198) 
days. Of 141 initiated on IPT, 133 (94%, 95% CI 89.1% 
to 97.5%) completed 6 months of therapy. Eight patients 
(6%) did not complete IPT; five were lost to follow-up 
and three discontinued due to adverse drug effects. Eligi-
bility for IPT, IPT initiation and completion rates are 
described in figure 1. The IPT initiation rate ranged from 
0% to 57% across 11 ART centres (figure 2 and online 
supplementary table 1).
Sociodemographic and clinical characteristics associ-
ated with non-initiation of IPT are described in table 2 
and table 3. Non-initiation was higher among children 
(78%) and elderly (83%) compared with PLHIV aged 
45–59 years (64%). Non-initiation rate was higher among 
migrant workers (82%). All PLHIV who were not on ART 
(n=11) had not been initiated on IPT. In adjusted anal-
ysis, age more than 60 years (RR-1.3, 95% CI 1.1 to 1.7), 
migrant worker (RR-1.3, 95% CI 1.1 to 1.4) and non-ini-
tiation of ART (RR-1.4, 95% CI 1.1 to 1.8) were inde-
pendently associated with higher rates of non-initiation 
of IPT.
sensitivity analysis
Considering about 10% of those without active TB at 
registration would have been found to be ineligible for 
IPT, about 431 (87.3%) would have been eligible for IPT 
initiation. Considering 141 individuals were started on 
IPT among those eligible based on sensitivity analysis, the 
IPT initiation rate would be 32.7% (141 out of431).
Figure 1 Flow diagram depicting eligibility, initiation and 
completion of IPT among PLHIV registered between January 
2016 and December 2017 in the Far-Western Region of 
Nepal. *Those without active TB were considered eligible 
for IPT due to lack of information on liver disease, active 
alcohol use, jaundice, prior isoniazid resistance, peripheral 
neuropathy and unexplained illness. IPT, isoniazid preventive 
therapy; PLHIV, people living with HIV; TB, tuberculosis.
Table 1 Sociodemographic and clinical characteristics 
of PLHIV registered between January 2016 and December 
2017 in the Far-Western Region of Nepal, n=492
Characteristics Categories Number (%)
Total 492 (100)
Age groups (years) <15 40 (8.1)
15–29 89 (18.1)
30–44 225 (45.7)
45–60 123 (25.0)
≥60 15 (3.0)
Gender Male 267 (54.3)
Female 224 (45.5)
Others 1 (0.2)
Education Illiterate 78 (15.9)
Just literate* 70 (14.2)
Had formal education 39 (7.9)
Not recorded 305 (62.0)
Occupation Unemployed 20 (4.1)
Farmer 10 (2.0)
Housewife 87 (17.7)
Migrant worker 78 (15.9)
Others 22 (4.5)
Not recorded 275 (55.9)
Marital status Married 380 (77.2)
Unmarried 52 (10.6)
Widow/separated 60 (12.2)
CD4 count Less than 200 128 (26.0)
201–350 76 (15.4)
351–500 76 (15.4)
More than 500 69 (14.1)
Not recorded 143 (29.1)
WHO clinical 
staging
I and II 276 (56.1)
III and IV 183 (37.2)
Not recorded 33 (6.7)
ART regimen TLE regimen 421 (85.6)
Other regimen 60 (12.2)
Not initiated on ART 11 (2.2)
*Able to read and write but no formal education.
ART,  antiretroviral therapy; PLHIV, people living with HIV; 
TLE, tenofovir, lamivudine, efavirenz.
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DIsCussIOn
To our knowledge, this is the first study from Nepal 
assessing the IPT eligibility, initiation and completion rate 
among PLHIV in the programmatic setting after univer-
salisation of IPT in 2015. Though majority of PLHIV 
were eligible for IPT, only three out of 10 were initiated 
on IPT. Among those initiated on IPT, almost all (95%) 
completed 6 months of IPT.
In the current study, proportion of PLHIV eligible for 
IPT (97%) was found to be higher than those reported 
by previous studies.25 27 28 The study conducted in Kath-
mandu, Nepal during pilot phase of IPT implementa-
tion had reported about 87% of PLHIV to be eligible 
for IPT.27 This Kathmandu study also had considered all 
those without active TB as eligible for IPT, similar to the 
current study. Contrary to our study where a cohort of 
newly registered patients was included, the previous study 
was a cross-sectional study and had included PLHIV on 
care since several years. As risk of TB increases over time 
and ART initiation rate was low, there might have been 
relatively higher proportion of active TB patients (13%) 
in previous study compared with this study (3%).
Similar to our study, a study conducted in Malawi among 
newly registered PLHIV reported that about 2% were ineli-
gible for IPT as they had been diagnosed with active TB at 
registration.25 The Malawi study also reported that 9% were 
not eligible due to failure to for IPT due to at least one contra-
indication for initiating IPT. In the current study, except for 
details of TB symptom screening and diagnosis of TB, none 
of the other details on IPT eligibility were documented in 
the ‘ART registers’. This might be either due to poor compli-
ance to IPT eligibility testing itself or deficiency in documen-
tation of these examination details.
In the current study, we found the IPT coverage rate (30%) 
to be relatively poor compared with other studies.25 28 36 The 
current study had poor IPT coverage even after adjusting 
for overestimation of IPT eligibility (33%).25 28 36 Low IPT 
coverage may be due to several structural and provider level 
deficiencies in the FWR of Nepal. The poor infrastructure 
in health facilities for assessing eligibility, limited manpower, 
untrained health workforce, poor adherence to guidelines, 
interrupted drug supply and drug stock-outs, and lack of 
monitoring on IPT eligibility, initiation and completion rates 
might have led to low coverage of IPT in FWR of Nepal. The 
IPT initiation rates varied across the ART centres (0%–56%) 
within FWR indicating that IPT coverage rates are by large 
dependent on ART centres and therefore, indirectly related 
to infrastructural and provider capacity of the centre. Also, 
patient groups like old age, migrant worker and those not 
initiated on ART had very low coverage of IPT.
The HIV care programme recommends initiating IPT 
among eligible PLHIV at the time of registration. Even if 
IPT is not initiated during registration, it needs to be initi-
ated within the next few visits to ART centre. However, only 
18% of the PLHIV were initiated on IPT within 3 months 
of being eligible at the time of registration. Initiation of 
IPT after 3 months might not reflect the health system 
response for IPT eligibility assessment done at the time of 
registration. Majority of the previous studies were cross-sec-
tional studies and had considered ‘ever initiated on IPT’ to 
Figure 2 Map depicting the ART centres of the Far-Western Region of Nepal with IPT initiation rate among PLHIV registered 
between January 2016 and December 2017. Source for Nepal admin shape files is http://diva-gis.org/download which is free 
and open source. Software used to create figure 2, QGIS (previously known as Quantum GIS), is a free and open source cross 
platform desktop geographic information system (GIS) application that supports viewing, editing and analysis of geospatial 
data. ART, antiretroviral therapy; IPT, isoniazid preventive therapy; PLHIV, people living with HIV. 
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define IPT coverage. The IPT initiation rate within 3 months 
of eligibility provides a better monitoring indicator which 
covers both IPT coverage and timeliness of initiation of IPT. 
Consistent with the other studies, the IPT completion rates 
were high (94%) in the current study.23–28 36 37 Hence, it can 
be reasoned that the hurdle for prevention of TB among 
PLHIV is low rate of IPT initiation.
Along with IPT coverage and completeness, some more 
programmatically relevant aspects were noted during this 
study. The ‘ART register’ was incomplete with details on 
education and occupation missing for more than half 
of the registered PLHIV. The CD4 count at registration, 
which is used to assess the immunological improvement 
and decide on the course of ART was not available in 
about one-third of the registered PLHIV. In contrast to 
incompleteness of documentation and low IPT coverage, 
the study setting had a high ART initiation rate (98%), 
which was appreciable. This high ART initiation rate may 
be due to adoption of ‘test and treat’ strategy, improved 
efforts of the NCASC in procurement and supply of ART 
drugs, frequent training of all the NCASC and health staff 
regarding ART and use of ART initiation rate as an indi-
cator to monitor the performance of ART centre. Lessons 
learnt in improving the ART coverage can be considered 
to improve the IPT coverage in study setting.
This study has a few strengths. First, this is the first study 
assessing the IPT coverage in the programme setting of 
resource limited Far-Western Region of Nepal. Second, there 
was no selection bias as all the PLHIV registered for care in 
the 11 ART centres of Far-Western Region were included. 
Table 2 Sociodemographic factors associated with non-initiation of IPT among PLHIV registered between January 2016 and 
December 2017 in the Far-Western Region of Nepal, n=477
Characteristic Total, N (%)*
Not initiated on IPT,  
N (%)†
Unadjusted RR 
(95% CI)
Adjusted RR  
(95% CI)
Total 477 (100) 336 (70.4)
Age groups (years)
  <15 40 (8.4) 31 (77.5) 1.2 (1.0 to 1.5) 1.3 (0.7 to 2.4)
  15–29 89 (18.6) 63 (70.8) 1.1 (0.9 to 1.3) 1.1 (0.9 to 1.4)
  30–44 221 (46.3) 155 (70.1) 1.1 (0.9 to 1.3) 1.1 (0.9 to 1.3)
  45–59 98 (20.5) 63 (64.3) 1 1
  ≥60 29 (6.07) 24 (82.8) 1.3 (1.0 to 1.6) 1.3 (1.1 to 1.7)
Gender
  Male 253 (53.0) 182 (72.0) 1.0 (0.9 to 1.2) 1.0 (0.8 to 1.1)
  Female and others 224 (46.9) 154 (68.8) 1 1
Education
  Illiterate 78 (16.3) 65 (83.3) 1.2 (0.9 to 1.5) 1.2 (0.9 to 1.5)
  Just literate§ 70 (14.7) 54 (77.1) 1.1 (0.9 to 1.4) 1.0 (0.9 to 1.2)
  Had formal education 38 (8.0) 27 (71.1) 1 1
  Not recorded 291 (61.0) 190 (65.3) 0.9 (0.7 to 1.1) 0.9 (0.7 to 1.2)
Occupation
  Unemployed 20 (4.2) 16 (80.0) 1.1 (0.7 to 1.8) 1.0 (0.8 to 1.4)
  Farmer 10 (2.1) 7 (70.0) 1 1
  Housewife 87 (18.2) 66 (75.9) 1.1 (0.7 to 1.7) 1.2 (1.0 to 1.4)
  Migrant worker 77 (16.1) 63 (81.8) 1.2 (0.8 to 1.8) 1.3 (1.1 to 1.4)
  Others 22 (4.6) 15 (68.2) 1.0 (0.6 to 1.6) 0.9 (0.6 to 1.5)
  Not recorded 261 (54.7) 169 (64.8) 0.9 (0.6 to 1.4) 1.1 (0.9 to 1.4)
Marital status
  Married 367 (76.9) 266 (72.5) 1.4 (1.1 to 1.7) 1.2 (1.0 to 1.5)
  Unmarried 52 (10.9) 39 (75.0) 1.4 (1.1 to 1.9) 1.3 (0.8 to 2.0)
  Widow/separated 58 (12.2) 31 (53.5) 1 1
*Column percentage.
†Row percentage.
‡Cluster adjusted (ART centres) generalised linear (Poisson) model; those categories (except ‘not recorded’ and ‘others’) with lowest 
proportion of IPT non-initiation were considered as reference categories in the model.
§Able to read and write but no formal education.
ART,  antiretroviral therapy; IPT, isoniazid preventive therapy;  PLHIV,  people living with HIV; RR, relative risk.  on
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Third, about 10% data extraction forms were rechecked by 
the principal investigator for data quality. Fourth, data quality 
was assured as data was double entered and validated using 
EpiData software. Fifth, the Strengthening the Reporting of 
Observational Studies in Epidemiology checklist has been 
used for reporting this study.
This study has a few limitations. First, secondary data 
were used which had missing information on few socio-
demographic details. Also, recording errors and incom-
pleteness of documentation cannot be ruled out. Second, 
the proportion eligible for IPT might have been over-
estimated, as only all those PLHIV without active TB 
could be considered as eligible for IPT. However, we have 
conducted sensitivity analysis to derive the eligibility and 
initiation rate estimates adjusting for this overestimation. 
Third, the study was not powered to find association 
between baseline characteristics of PLHIV and initiation 
of IPT. Also, the model developed for assessing the inde-
pendent effect of patient level characteristics on IPT initi-
ation might be deficient as few important confounders 
like socioeconomic status, migration and adherence to 
ART could not be included in it. Fourth, completeness of 
IPT was assessed based on the receipt of IPT drugs during 
six consecutive visits and did not take into consideration 
the adherence to drugs.
Few recommendations can be put forth based on the find-
ings of this study. First, there is need for carrying out clin-
ical and laboratory examinations to assess the eligibility for 
IPT and document the details of the same in ‘ART register’. 
The ‘ART register’ needs to be restructured with inclusion 
of appropriate columns (fields?) to document the details 
of assessment of IPT eligibility, which is currently not avail-
able. Second, the programme monitoring and supervision 
needs to be strengthened and special emphasis needs to be 
given on completeness of records. Third, the programme 
managers need to explore the possible reasons for low initia-
tion rates of IPT using qualitative research methods and take 
corrective actions based on those findings. Fourth, cohort-
based IPT initiation rate can be added as an indicator in the 
quarterly reporting formats of ART centre and also used for 
monitoring the programme implementation.
COnClusIOn
In FWR of Nepal, about three out of 10 eligible PLHIV are 
receiving IPT. Among those who have received IPT, the 
completion rate was good. The HIV care programme needs 
to explore the potential reasons for this low coverage and take 
context-specific corrective action to fix this gap.
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Table 3 Clinical factors associated with non-initiation of IPT among PLHIV registered between January 2016 and December 
2017 in the Far-Western Region of Nepal, n=477
Characteristic Total, N (%)*
Not initiated on IPT,  
N (%)†
Unadjusted RR 
(95% CI)
Adjusted RR  
(95% CI)‡
Total 477 (100) 336 (70.4)
CD4 count
  Less than 200 124 (26.0) 92 (74.2) 1.0 (0.9 to 1.3) 1.1 (0.9 to 1.3)
  200–350 73 (15.3) 44 (60.3) 0.8 (0.7 to 1.1) 0.9 (0.7 to 1.1)
  350–500 74 (15.5) 40 (54.1) 0.8 (0.6 to 1.0) 0.8 (0.7 to 0.9)
  More than 500 69 (14.7) 49 (71.0) 1 1
  Not recorded 137 (28.7) 111 (81.0) 1.1 (1.0 to 1.4) 1.2 (0.9 to 1.6)
WHO clinical staging
  I or II 274 (57.4) 195 (71.2) 1.0 (0.9 to 1.2)
  III or IV 172 (36.1) 119 (69.2) 1
  Not recorded 31 (6.5) 22 (71.0) 1.0 (0.8 to 1.3)
ART status
  On ART 466 (97.7) 325 (69.7) 1 1
  Not initiated on ART 11 (2.3) 11 (100) 1.5 (1.4 to 1.6) 1.4 (1.1 to 1.8)
*Column percentage.
†Row percentage.
‡Cluster adjusted (ART centres) generalised linear (Poisson) model; those categories (except ‘not recorded’ and ‘others’) with lowest 
proportion of IPT non-initiation were considered as reference categories in the model.
ART, antiretroviral therapy; IPT, isoniazid preventive therapy; PLHIV,  people living with HIV; RR, relative risk.
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